A cancer expert has shared the five types of cancer which are considered the most "lethal", and claimed people diagnosed with ...
Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.
Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.
The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.
Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.
Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...
U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
Dr. Waqqas Tai is a cancer doctor who often shares health advice online. He recently revealed what the five most "lethal" ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results